The Gaithersburg biotechnology company, Novavax, announced Monday morning data from phase 3 of its COVID-19 vaccine trials which were conducted in the United States and Mexico. Novavax found that the trial, which began in December and enrolled 29,960 participants, had an overall efficacy rate of 90.04%. Last year, Novavax was awarded $1.6 billion from the … Continue reading Novavax Says Its COVID-19 Vaccine Shows 90% Efficacy Rate